Role of Mosapride in Patients With Gastroesophageal Reflux Disease

• Status: Completed
• Trial end date: 2009-05-01
• Target enrollment: 0
• Participant gender: All

Summary

Gastroesophageal reflux disease (GERD) is a very common disease in the Western World. In Taiwan, this disease is increasing gradually because the investigators' eating style is closing to Western world.

Proton pump is the main drug for patients with GERD in the past two decades. Prokinetic agent is an important adjuvant to the therapy of GERD. This study aims to evaluate the role of prokinetic agent in the management of GERD.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Lotung Poh-Ai Hospital
• Collaborator: Tomorrow Medical Foundation
• Treatments: Dexlansoprazole; Lansoprazole; Mosapride

Criteria

Inclusion Criteria:

• Aged between 18 and 90 years old

• Outpatients

• Characteristic GERD symptoms: acid regurgitation, heart burn, or belching

• Erosive esophagitis on upper digestive endoscopy, based on Los Angeles classification

Exclusion Criteria:

• History of allergy to lansoprazole or mosapride

• Pregnant or lactating women

• Uremia

• Decompensated liver disease

• Age under 18 and over 90 years-old

• Lack of informed consent